Excellent for the patient, not so much for shareholders.If IMU's...

  1. 4,506 Posts.
    lightbulb Created with Sketch. 4654
    Excellent for the patient, not so much for shareholders.

    If IMU's market opportunities are limited to Cholangiocarcinoma and DLBCL, then it's a lot of risk for not much upside. These are highly competitive markets. CF33 and Azer-Cel will have to demonstrate a marked improvement to efficacy for any chance of commercial success.

    Cholangiocarcinoma

    Numerous drugs approved for this indication. https://www.cancer.org/cancer/types/bile-duct-cancer/treating/targeted-therapy.html

    DLBCL

    https://hotcopper.com.au/data/attachments/6726/6726152-c6cb7358429692ab07915a22cb37d47e.jpg
    https://www.lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/dlbcltreatment/

    And these are the DLBCL drugs currently undergoing P2-3 trials:

    https://hotcopper.com.au/data/attachments/6726/6726144-4582269184c98aab3743408527c78dcd.jpg

    https://lymphoma.org/wp-content/uploads/2023/06/LRF_DLBCL_Fact_sheet.pdf?_gl=1*7ifrh3*_gcl_au*MTY3MDc4ODkwMi4xNzM2NDc5NzA4


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.2¢
Change
0.001(9.09%)
Mkt cap ! $89.60M
Open High Low Value Volume
1.2¢ 1.4¢ 1.1¢ $588.2K 47.67M

Buyers (Bids)

No. Vol. Price($)
32 8539697 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.3¢ 4389150 26
View Market Depth
Last trade - 15.50pm 27/06/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.